Viewing Study NCT05844202

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2025-12-26 @ 2:23 AM
Study NCT ID: NCT05844202
Status: COMPLETED
Last Update Posted: 2023-05-06
First Post: 2023-05-02
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
Sponsor: Alvea Holdings, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Sars-CoV-2 Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sars View
None Sars-CoV-2 View
None COVID-19 View
None Vaccine View
None pDNA View
None plasmid DNA View
None COVID19 View